{"id":"quinapril-losartan","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL1162799","moleculeType":"Small molecule","molecularWeight":"909.12"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Quinapril is an ACE inhibitor that prevents conversion of angiotensin I to angiotensin II, while losartan is an angiotensin II receptor blocker (ARB) that directly blocks AT1 receptors. Together, they provide dual RAAS inhibition through complementary mechanisms, resulting in enhanced vasodilation, reduced aldosterone secretion, and greater blood pressure reduction than either agent alone.","oneSentence":"This combination blocks two different pathways in the renin-angiotensin-aldosterone system (RAAS) to lower blood pressure: quinapril inhibits ACE while losartan blocks angiotensin II receptors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:03:28.741Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure"}]},"trialDetails":[{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":"Post-stroke Pneumonia","enrollment":13656},{"nctId":"NCT05498675","phase":"","title":"Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2021-09-01","conditions":"Sacubitril/Valsartan, Hypertension, Obesity","enrollment":180},{"nctId":"NCT06515678","phase":"","title":"Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2024-05-20","conditions":"Ovarian Cancer, Antiangiogenic-Associated Hypertension, Adjuvant Bevacizumab","enrollment":9464},{"nctId":"NCT02817360","phase":"PHASE4","title":"NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients","status":"RECRUITING","sponsor":"Martin Huelsmann","startDate":"2016-02","conditions":"Heart Diseases, Diabetes Mellitus, Type 2","enrollment":2400},{"nctId":"NCT05713396","phase":"PHASE4","title":"Diabetic Autonomic Neuropathy and Left Ventricular Function","status":"COMPLETED","sponsor":"AHEPA University Hospital","startDate":"2017-01-01","conditions":"Diabetes Mellitus","enrollment":59},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT00159692","phase":"PHASE4","title":"Amlodipine Diabetic Hypertension Efficacy Response Trial","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-03","conditions":"Hypertension","enrollment":739},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT01715584","phase":"PHASE4","title":"Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2012-07","conditions":"Hypertension","enrollment":80},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":62,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Quinapril + Losartan","genericName":"Quinapril + Losartan","companyName":"AHEPA University Hospital","companyId":"ahepa-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Quinapril is a small molecule angiotensin-converting enzyme inhibitor, and Losartan is a small molecule angiotensin receptor blocker. Both Quinapril and Losartan have been studied in various clinical trials for conditions such as hypertension, post-stroke pneumonia, and diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}